We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy male subjects. DuP 532 (1 to 200 mg) was well tolerated, with no effect on blood pressure or heart rate. Compared with losartan (100 mg), DuP 532 (200 mg) was a weak antagonist of pressor responses to intravenous angiotensin II. Maximum inhibition of diastolic pressor response was 86% (95% confidence interval [CI], 84%, 88%) approximately 4.6 hours after losartan and 48% (95% CI, 38%, 56%) 8.7 hours after DuP 532. Twenty-four hours after dosing, inhibition by losartan and DuP 532 was similar (40% to 45%). DUP 532 is extensively bound in human plasma, with an in vitro free fraction of 0.06. Although DuP 532 and EXP3174 (losartan's active metabo...
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of th...
We assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor a...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
This study was conducted to assess the pharmacologic properties of the new orally active angiotensin...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
BACKGROUND: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin ...
Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
This series of studies was designed to assess in normal volunteers the relationships between various...
Several orally active non-peptide angiotensin II subtype 1 (AT1) receptor antagonists are now availa...
This series of studies was designed to assess in normal volunteers the relationships between various...
Use of angiotensin (Ang) II AT1 receptor antagonists for treatment of hypertension is rapidly increa...
INTRODUCTION: The evaluation of a new drug in normotensive volunteers provides important pharmacodyn...
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by ...
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of th...
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of th...
We assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor a...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
This study was conducted to assess the pharmacologic properties of the new orally active angiotensin...
BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
BACKGROUND: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin ...
Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an oral...
This series of studies was designed to assess in normal volunteers the relationships between various...
Several orally active non-peptide angiotensin II subtype 1 (AT1) receptor antagonists are now availa...
This series of studies was designed to assess in normal volunteers the relationships between various...
Use of angiotensin (Ang) II AT1 receptor antagonists for treatment of hypertension is rapidly increa...
INTRODUCTION: The evaluation of a new drug in normotensive volunteers provides important pharmacodyn...
Losartan is an orally active angiotensin II antangonist that selectively blocks effects mediated by ...
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of th...
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of th...
We assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor a...
We assessed the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, o...